Search is Powered by Google
Lymphoma / Leukemia News

Drug Prevents Disease In Mouse Model Of Leukemia

Main Category: Lymphoma / Leukemia
Also Included In: Clinical Trials / Drug Trials;  Biology / Biochemistry
Article Date: 27 Aug 2007 - 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:2 stars

2 (1 votes)

Article Opinions: 0 posts

In a new study, Danilo Perrotti and colleagues from Ohio State University, Columbus, show that treatment with a drug known as FTY720 prevents disease in a mouse model of many leukemias caused by the cancer protein BCR-ABL (nearly all cases of blast crisis chronic myeloid leukemia [CML-BC] and some cases of acute lymphocytic leukemia [ALL]). As the drug also induced cell lines from humans with these leukemias to die in vitro the authors suggest that FTY720 should be considered by researchers and clinicians developing new approaches to treat CML-BC and ALL patients.

FTY720 was chosen for these studies because it does not directly target the BCR-ABL kinase, which in individuals with CML-BC and ALL is resistant to kinase inhibitors such as imatinib (Gleevec). Instead, FTY720 activates protein phosphatase 2A (PP2A), which is a tumor suppressor that is inactivated by signals induced by BCR-ABL. The pharmacologic doses of FTYY720 used to suppress leukemogenesis in the mice had no adverse effects and FTY720 has thus far shown no adverse effects in clinical trials testing its potential as a therapeutic for the treatment of multiple sclerosis. The authors therefore believe their data provide strong support for the use of FTY720 as a novel therapeutic for CML-BC and ALL patients that are not responsive to treatment with kinase inhibitors.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

TITLE: FTY720, a new and alternative strategy for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

AUTHOR CONTACT:
Danilo Perrotti
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.

Source: Karen Honey
Journal of Clinical Investigation




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Case Of Patient "Cured" Of HIV Baffles Doctors
14 Nov 2008
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been "cured" by a bone marrow transplant given to treat his acute myeloid leukemia...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating Lymphoma Early image Treating Lymphoma Early

Non-Hodgkin's lymphoma is a cancer of the immune system. First-line treatment options include radiation therapy, chemotherapy, immunotherapy, radioimmunotherapy and stem cell transplant. How do you figure out which is right for you...

View more videos...